CD19-CAR T cells reset the EBV + autoreactive B cell repertoire in autoimmune disease

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Epstein-Barr virus (EBV) reprograms autoreactive B cells into activated antigen-presenting cells that drive pathogenic T- and B-cell responses in autoimmune disease. 1–4 Whether eliminating these cells contributes to durable remission after CD19 chimeric antigen receptor (CAR) T-cell therapy 5–7 is unknown. Here, using EBV B-cell sequencing (EBV-seq) 3 , we profiled EBV + B cells from patients treated with CD19-CAR T cells (systemic lupus erythematosus, n=6; inflammatory myopathy, n=3; systemic sclerosis, n=3) or rituximab (n=15) and recombinantly expressed their antibodies to define antigen specificity. At baseline, EBV + B cells were enriched relative to healthy donors, class-switched and hypermutated, expressed the latency III program with heightened antigen-presentation signatures, and encoded autoantibodies. CAR T cells, but not rituximab, depleted EBV + B cells and shifted the reconstituted repertoire towards IgM + , minimally mutated, largely non-autoreactive cells, consistent with infection of newly generated B cells. After rituximab, EBV + B cells retained a class-switched, hypermutated and autoreactive with an activated antigen-presenting phenotype. Sustained drug-free remission occurred in 8/12 CAR T-cell-treated versus 0/15 rituximab-treated patients. In vitro , EBV + B cells resisted anti-CD20 and anti-CD19 antibodies but were killed by CAR T cells and a CD19 T-cell engager. Our findings suggest resetting the EBV + autoreactive B-cell repertoire contributes to sustained drug-free remission.

Article activity feed

  1. Source: www.biorxiv.org/content/10.6... Full study (PDF): www.biorxiv.org/content/10.6...

  2. CD19-CAR T cells clear the EBV-infected B cells that carry autoreactive antibodies. Rituximab doesn’t. That may be why only one of them produces lasting remission. New Robinson Lab preprint led by me and Mahesh Pandit. 🧵 www.biorxiv.org/content/10.6...

  3. Stanford researchers studied 27 autoimmune patients and found CD19 CAR T-cell therapy cleared EBV-infected, autoreactive B cells that resisted rituximab. 8 of 12 CAR T-cell patients achieved sustained drug-free remission. www.biorxiv.org/content/10.6...

  4. CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease https://www.biorxiv.org/content/10.64898/2026.10.24.761515v1

  5. CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease https://www.biorxiv.org/content/10.64898/2026.10.24.761515v1